Physician

Tracy Alan Bridges, MD

According to 2025 Medicare claims, Tracy Bridges, MD (NPI: 1386749117) practices allergy/immunology in the Albany, GA market, with the plurality of this provider's patient population coming from Dougherty, GA. This provider's primary affiliated billing organization is ALLERGY & ASTHMA CLINICS OF GA (NPI: 1093997447; TIN: 582123289) and primary practice location at 31707-1282.

Bridges' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 320 traditional Medicare patients, billed 12,422 HCPCS/CPT codes, and received $180,534 in Medicare payments. The top billing code was 99205 (New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more). Part D data shows 5,369 prescription claims across 506 beneficiaries totaling $2,578,551 in drug costs, led by Haegarda (C1 Esterase Inhibitor). DME data shows 825 claims. Open Payments data shows 171 records totaling $95,760. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has moved up and down with repeated peaks and valleys, starting at $154,391 and ending at $180,534. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $291,388 to $2,578,551. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $31,706 and ending at $28,195.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	433	12,280	$154,391
2016	489	11,952	$152,944
2017	495	16,099	$241,764
2018	496	13,672	$229,088
2019	554	14,456	$266,809
2020	436	7,783	$163,433
2021	454	8,032	$150,636
2022	372	5,925	$126,565
2023	314	6,167	$117,861
2024	320	12,422	$180,534

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	378	2,979	$291,388
2016	425	3,630	$359,445
2017	450	4,135	$516,062
2018	486	4,781	$944,436
2019	513	4,945	$1,308,852
2020	521	5,063	$1,195,021
2021	573	5,165	$1,654,949
2022	540	4,747	$2,436,375
2023	502	4,887	$2,704,408
2024	506	5,369	$2,578,551

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	99	1,012	$1,184,860
2016	124	1,307	$1,808,507
2017	107	1,319	$1,599,862
2018	112	1,513	$1,853,306
2019	81	1,400	$1,861,016
2020	157	1,572	$2,366,827
2021	109	1,409	$2,353,029
2022	73	1,151	$1,883,328
2023	61	851	$1,479,844
2024	53	825	$1,492,540

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99205	New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more	41	41	$139
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	242	388	$83
94010	Test to measure expiratory airflow and volume	71	102	$17
95012	Test to measure the level of nitric oxide gas	64	92	$12
95004	Test for allergy using allergenic extract	52	4,101	$3

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Haegarda	C1 Esterase Inhibitor	26	728	$839,912
Dupixent Syringe	Dupilumab	99	2,758	$389,003
Tezspire	Tezepelumab-Ekko	54	1,512	$234,446
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	218	8,160	$172,054
Xolair	Omalizumab	50	1,283	$165,528

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J1558	Injection, immune globulin (xembify), 100 mg	N	12	128	$660,795
J1555	Injection, immune globulin (cuvitru), 100 mg	N	N/R	46	$247,078
J1575	Injection, immune globulin/hyaluronidase, (hyqvia), 100 mg immuneglobulin	N	N/R	27	$218,282
J1576	Injection, immune globulin (panzyga), intravenous, non-lyophilized (e.g., liquid), 500 mg	N	N/R	28	$117,450
J1559	Injection, immune globulin (hizentra), 100 mg	N	N/R	27	$115,074

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	169	$89,402	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$6,359	Eli Lilly and Company
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Tracy Alan Bridges, MD?

Tedicare shows public-source Medicare data for Tracy Alan Bridges, MD (NPI 1386749117), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Tracy Alan Bridges, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Tracy Alan Bridges, MD?

Tracy Alan Bridges, MD is linked to ALLERGY & ASTHMA CLINICS OF GA (billing NPI 1093997447) in the available physician profile data.

Does Tracy Alan Bridges, MD have Open Payments data?

Tracy Alan Bridges, MD has 171 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.